10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Genentech announced late Wednesday that the US Food and Drug Administration has approved Xofluza (baloxavir marboxil) for the treatment of acute, uncomplicated influenza, or flu, in people 12 years of age and older who have had flu symptoms for no more than 48 hours. 25 October 2018
In its initial public offering (IPO) on the Hong Kong Stock Exchange, China’s Innovent Biologics has reportedly sold around $421 million worth of shares priced at the top end of estimates, at about $1.78 per share. 25 October 2018
US companies Dicerna Pharmaceuticals and Alexion Pharmaceuticals today announced a research collaboration and license agreement to discover and develop novel GalXC RNAi therapeutics for the treatment of complement-mediated diseases. 24 October 2018
The UK Secretary of State for Health and Social Care has announced that the PCSK9 inhibitor class has been selected as a treatment that needs to see a rapid increase in uptake to ensure that patients, and the National Health Service (NHS), get the benefits of this class of medicines. 24 October 2018
Beijing’s CANbridge Pharmaceutical and Shanghai’s WuXi Biologics have entered into a strategic partnership to develop and sell rare disease therapies. 24 October 2018
Canadian drugmaker Zymeworks closed Tuesday’s trading more than 2% up after announcing that it had signed a deal with the privately-held Danish dermatology specialist, LEO Pharma. 24 October 2018
Campaign group Médecins Sans Frontières (MSF) has called on Johnson & Johnson to slash the price of its tuberculosis (TB) drug Sirturo (bedaquiline) by 50%. 24 October 2018
US biotech Celgene has appointed Dr Alise Reicin as president, global clinical development, reporting to Mark Alles, chairman and chief executive, effective November 1, 2018. 24 October 2018
US biotech major Biogen today posted strong third-quarter 2018 financials, showing that total revenues of $3.4 billion increased 12% versus the like prior-year period, just beating analysts’ estimates of $3.33 billion. 23 October 2018
Simon Jose, a Brit who has spent more than 30 years in pharma, is to become chief commercial officer of Idorsia, the research-based spin-out from Actelion following the latter’s acquisition by Johnson & Johnson. 23 October 2018
French biotech firm Enterome has entered into a global licensing, co-development and co-promotion agreement with Japan’s Takeda Pharmaceutical. 23 October 2018
The race to grab market share in the migraine space is becoming one of the most keenly-watched in pharma – and Aimovig (erenumab) is forecast to be the top-selling drug by 2026. 23 October 2018
AstraZeneca and its global biologics research and development arm MedImmune are expanding their presence in the competitive immuno-oncology (I-O) with a new deal and equity stake in a French biotech firm. 23 October 2018
Shares in Bristol-Myers Squibb fell 6% on Monday, after the firm made public regulatory setbacks in the USA and Europe related to its Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) combination therapy. 23 October 2018
UK-headquartered Hemogenyx is collaborating with US biopharma Orgenesis to rapidly develop and bring to market its human postnatal hemogenic endothelial cell technology (Hu-PHEC). 22 October 2018
Bristol-Myers Squibb could now have to wait till May 2019 to hear if the US Food and Drug Administration (FDA) has approved its supplemental Biologics License Application (sBLA) for the use of Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) in metastatic first-line non-small cell lung cancer. 22 October 2018
The US Food and Drug Administration has granted Rare Pediatric Disease (RPD) designation to lonafarnib in the treatment of both Hutchinson-Gilford Progeria Syndrome (HGPS or progeria) and progeroid laminopathies. 22 October 2018
Merck & Co has presented striking data in head and neck cancer which, in line with the theme of this year’s ESMO congress, demonstrate the growing breadth of indications in which immune modulation may be an effective strategy. 22 October 2018
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024